Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2022-04-19 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
关于向激励对象授予第一期股权激励计划预留股票期权的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Beijing Northland Biotech Co., Ltd. regarding the granting of reserved stock options under the company's first equity incentive plan. It details the board and supervisory approvals, conditions for granting, the number of options granted, the exercise price, and the legal and financial opinions supporting the grant. The document is a formal disclosure about a stock option grant to incentive recipients, including detailed terms and conditions, but it is not a full financial report, earnings release, or management discussion. It is not a proxy solicitation or voting result announcement. The content fits the category of a Capital/Financing Update as it relates to changes in the company's capital structure through stock option grants. The document length (7400 characters) and detailed content confirm it is the announcement itself, not a brief report publication notice or a certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-04-19 Chinese
关于签订生物药物产业化项目建设工程施工合同的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a construction contract for a biopharmaceutical industrialization project by the company's controlling subsidiary. It includes details about the contract, the parties involved, the board meeting resolution approving the contract, and the impact on the company. There are no financial statements, quarterly or annual results, or detailed financial analysis. The document is a corporate announcement about a contract signing and project update, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is best classified as a Regulatory Filing (RNS) because it is a general corporate announcement that does not fit other specific categories.
2022-04-05 Chinese
第五届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 17th meeting of the 5th Board of Directors of Beijing Northland Biotech Co., Ltd. It details the meeting date, attendance, agenda items, and voting results. The content focuses on board decisions, specifically the approval of a construction contract by a subsidiary. There is no financial report, earnings data, or regulatory filing of financial results. The document is clearly a Board/Management Information announcement about board meeting resolutions and decisions, not an annual report, audit report, or other financial filing. Therefore, the appropriate classification is MANG (Board/Management Information). The document length and content support high confidence in this classification.
2022-04-05 Chinese
发行注册环节反馈意见落实函
Capital/Financing Update Classification · 95% confidence The document is a communication regarding the registration process for a securities issuance, specifically referencing feedback from the China Securities Regulatory Commission (CSRC) on the registration phase. It discusses the company's fundraising plans, use of proceeds, and regulatory compliance related to the issuance. The document is short (869 characters) and primarily serves as a regulatory feedback and instruction letter rather than a full financial report or detailed filing. It does not contain financial statements or detailed financial analysis but is a regulatory communication related to capital raising. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-03-24 Chinese
关于收到发行注册环节反馈意见落实函的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (674 characters) regarding the receipt of feedback from the Beijing Stock Exchange and the China Securities Regulatory Commission (CSRC) about the company's application for a specific share issuance. It states that the company will respond to the feedback and that the issuance is subject to CSRC approval. There is no financial data, no detailed report, and no indication that this is a full report or financial statement. The document is an update on the capital raising process and regulatory feedback, fitting the category of Capital/Financing Update (CAP).
2022-03-24 Chinese
关于接待机构投资者调研情况的公告
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the reception of institutional investor research and includes detailed Q&A about the company's projects, stock issuance progress, and stock lock-up status. It is not a financial report, earnings release, or regulatory filing of financial results. It is a disclosure of investor relations activity and company updates related to financing and stock issuance. The document length is 2238 characters, which is relatively short and focused on investor communication rather than a full report. The content aligns best with a Capital/Financing Update (CAP) as it discusses the progress of a specific stock issuance and related project financing.
2022-03-14 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.